Navigation Links
Memory Pharmaceuticals Initiates Phase 2a Trial of MEM 3454 in Cognitive Impairment Associated with Schizophrenia
Date:12/20/2007

MONTVALE, N.J., Dec. 20 /PRNewswire-FirstCall/ -- Memory Pharmaceuticals Corp. (Nasdaq: MEMY) today announced dosing of the first subject in a randomized, double-blind, placebo-controlled Phase 2a clinical trial of MEM 3454, the Company's lead nicotinic alpha-7 receptor partial agonist, in cognitive impairment associated with schizophrenia (CIAS). The trial is designed to assess the safety, tolerability and cognitive effects of three doses of MEM 3454 in patients with CIAS. There are currently no drugs approved to treat CIAS.

"Cognitive impairment is a major component of schizophrenia that contributes to patients' inability to function," stated Stephen R. Murray, M.D., Ph.D., Chief Medical Officer of Memory Pharmaceuticals. "There is a strong rationale supporting the utility of MEM 3454 in CIAS, including the efficacy findings from our recently completed positive Phase 2a clinical trial of MEM 3454 in Alzheimer's disease. Given these findings, we are excited to assess the potential of MEM 3454 to improve cognitive impairments experienced by patients with schizophrenia. We currently expect to complete this trial in the fourth quarter of 2008."

The trial will enroll approximately 160 patients with stable schizophrenia who are receiving atypical antipsychotic therapy. Subjects will be randomized to receive 5 mg, 15 mg or 50 mg of MEM 3454 or placebo once daily for a period of eight weeks. The primary objective of the trial is to assess the effectiveness of MEM 3454 in CIAS using the MATRICS Consensus Cognitive Battery (MCCB). Secondary objectives include measures of other symptoms of schizophrenia and functional capacity.

Roche has an option to secure a worldwide, exclusive license to develop and commercialize MEM 3454 u
'/>"/>

SOURCE Memory Pharmaceuticals Corp.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Gladstone scientists uncover potential mechanism of memory loss in Alzheimers disease
2. Scientists synthesize memory in yeast cells
3. Penn engineers design computer memory in nanoscale form that retrieves data 1,000 times faster
4. Penn engineers design computer memory in nanoscale form that retrieves data 1,000 times faster
5. Scientists synthesize memory in yeast cells
6. Amarin Announces Publication of Pre-Clinical Memory Data in Journal of Neurochemistry
7. BioMedical Enterprises, Inc. (BME) Receives FDA Clearance for Spine Use of Its Memory Metal Implants
8. ASU researchers improve memory devices using nanotech
9. Memory Pharmaceuticals to Announce Third Quarter Results on Thursday, November 8, 2007
10. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
11. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... Lenexa, KS (PRWEB) April 21, 2015 Contract ... has announced plans to relocate into a new 41,500 ft2 ... XenoTech’s global headquarters, currently located at 16825 W. 116th St. ... and a half times the customized laboratory space, will remain ... where the company was founded more than twenty years ago. ...
(Date:4/21/2015)... 21, 2015 AbilTo, Inc., the nation,s leading ... submission has been accepted as a presentation to be ... taking place on June 5-6, 2015 in Boston, ... American Diabetes Association, the cost of diabetes to the ... a result of increased inpatient, outpatient, and pharmacy costs, ...
(Date:4/21/2015)... Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today ... Thursday, April 23, 4:30 p.m. ET. Participants are invited ... Investor call information: U.S./ ... number: (925) 418-7845 Participant Passcode: 32888538 Questions ... , tina.amirkiai@fleishman.com . Access will be ...
(Date:4/21/2015)...  Tute Genomics, a leading provider of cloud-based genomic medicine ... as VP of Marketing. Mr. Forsythe is the latest to ... its commercial operations over the last two quarters. ... is a tremendous addition to the Tute Genomics team," ... Genomics. "Josh,s vast experience commercializing software technology in a highly ...
Breaking Biology Technology:XenoTech Plans Expansion to New Global Headquarters after Impressive Revenue Growth in 2014 2XenoTech Plans Expansion to New Global Headquarters after Impressive Revenue Growth in 2014 3AbilTo To Present at the 2015 American Diabetes Association Annual Meeting on Remote Delivery of Behavioral Change Therapy 2AbilTo To Present at the 2015 American Diabetes Association Annual Meeting on Remote Delivery of Behavioral Change Therapy 3Ampio Announces Investor Call on Thursday, April 23, 4:30 p.m. ET 2Tute Genomics Continues Expansion of Genomic Medicine Commercial Operations; Appoints Josh Forsythe as New VP of Marketing 2Tute Genomics Continues Expansion of Genomic Medicine Commercial Operations; Appoints Josh Forsythe as New VP of Marketing 3Tute Genomics Continues Expansion of Genomic Medicine Commercial Operations; Appoints Josh Forsythe as New VP of Marketing 4
... AMLN ) will be presenting at the FBR ... 28, 2008 at 9:45 a.m. ET / 6:45,a.m. PT. ... Pharmaceuticals, will be providing a corporate overview., The ... a,recording will be made available following the event. The ...
... AstraZeneca (NYSE:,AZN) announced today that it supports ... the company,s latest step to provide the public,with ... Sponsored by Sens. Charles Grassley of Iowa ... a national registry of payments that,biopharmaceutical companies, device ...
... Biosciences,Corporation (Nasdaq: MATK ) announced that it intends ... 2008 on June 4, 2008, at approximately 4:00,p.m. Eastern ... Martek will,conduct a conference call to discuss the results ... interested parties may listen to the call,live via webcast ...
Cached Biology Technology:AstraZeneca Supports Transparency Legislation on Payments to Health Care Providers 2
(Date:4/14/2015)... April 14, 2015  HYPR Corp. today announced ... ® ) Alliance tm , an industry consortium ... commit to share technology and collaborate to deliver ... interoperable, more secure and private, and easier to ... verification that protects sensitive user information and eliminates ...
(Date:4/13/2015)... 2015 According to a ... Market Forecast & Opportunities, 2020", the global biometrics market ... 14% till 2020. The biometrics market is garnering ... and review of biometric management systems. The constant ... with greater efficiency, are resulting in increasing installation ...
(Date:4/10/2015)... April 10, 2015 Research and ... the "Security Competitive Profiles - NEC" report ... NEC will continue to supply a range ... market, with a company focus on the development of ... Winning opportunities in the Asia-Pacific ...
Breaking Biology News(10 mins):HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2NEC Security Competitive Profile 2015 2
... Scientists have been working for more than a ... genes within cells. Now researchers have discovered that microRNA ... each other and ultimately determine the types of cells ... implications in a wide range of fields, including medical ...
... ARBOR, Mich.---As a way to simplify lab-on-a-chip devices ... medical tests, University of Michigan researchers have created ... intelligently route the flow of electricity on computer ... the flow of fluid through their devices without ...
... available in <A HREF=",http://chinese.eurekalert.org/zh/pub_releases/2010-04/sfeb-phr042210.php,">Chinese . A ... extraordinarily complex fluctuations across a wide range of time ... clinical and dynamical significance it may provide warning ... the heart,s pacemaking system. In work published in ...
Cached Biology News:Production of biofuels could benefit by controlling the types of cells that develop in plants 2Microfluidic integrated circuit could help enable home diagnostic tests 2Microfluidic integrated circuit could help enable home diagnostic tests 3Periodic heart rate decelerations in premature infants 2Periodic heart rate decelerations in premature infants 3
Mouse monoclonal antibody to QPCT - glutaminyl-peptide cyclotransferase (glutaminyl cyclase)...
... MSY2/YBOX2 ( Abpromise for all ... Synthetic peptide derived from a ... human YBX2. (Note: the exact ... Entrez Gene ...
Rabbit polyclonal to YANK2 ( Abpromise for all tested applications). Antigen: A KLH conjugated synthetic peptide selected within aa 300~400 (C terminal region) of human YANK2. Entrez Gene ID:...
Certified by the Biological Stain Commission. For staining fresh peripheral blood smears and blood parasites....
Biology Products: